Daily Medication Pearl: Kovaltry (Antihemophilic Factor)

Kovaltry temporarily replaces the missing clotting Factor VIII in patients with hemophilia A.

Medication Pearl of the Day: Kovaltry (Antihemophilic Factor)

Indication: Kovaltry Antihemophilic Factor (Recombinant), is a recombinant, human DNA sequence-derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A.

Insight:

  • Dosing:
    • Required dose (IU) = body weight (kg) x desired Factor VIII rise (% of normal or IU/dL) x reciprocal of expected/observed recovery (e.g., 0.5 for a recovery of 2 IU/dL per IU/kg).
    • Estimated Increment of Factor VIII (IU/dL or % of normal) = [Total Dose (IU)/body weight (kg)] x 2 (IU/dL per IU/kg).
  • Dosage forms: Kovaltry is available as lyophilized powder in single-dose vials containing nominally 250, 500, 1000, 2000, or 3000 IU. Each vial of Kovaltry contains the labeled amount of recombinant Factor VIII in IU.
  • Adverse events: The most frequently reported adverse reactions in clinical trials (≥5%) were inhibitors in previously untreated patients/minimally treated patients, pyrexia, headache, and rash.
  • Mechanism of action: Kovaltry temporarily replaces the missing clotting Factor VIII that is needed for effective hemostasis.
  • Manufacturer: Bayer

Sources: